Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a sell rating to a hold rating in a report released on Tuesday.

Several other research firms have also issued reports on KURA. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Wednesday, November 6th. Wedbush restated an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a report on Monday, November 4th. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, UBS Group started coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Up 5.8 %

Shares of KURA stock opened at $18.57 on Tuesday. The firm’s fifty day moving average price is $18.67 and its two-hundred day moving average price is $19.99. Kura Oncology has a 1 year low of $8.17 and a 1 year high of $24.17. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.42 billion, a P/E ratio of -7.87 and a beta of 0.86.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Algert Global LLC boosted its holdings in shares of Kura Oncology by 4.4% during the third quarter. Algert Global LLC now owns 272,276 shares of the company’s stock worth $5,320,000 after acquiring an additional 11,493 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Kura Oncology by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock worth $12,212,000 after purchasing an additional 14,106 shares during the last quarter. Intech Investment Management LLC bought a new stake in Kura Oncology in the 3rd quarter valued at $298,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Kura Oncology by 35.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock valued at $579,000 after buying an additional 7,722 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its position in Kura Oncology by 21.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock worth $924,000 after buying an additional 8,505 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.